Official United States Air Force Website
The Pathology department prepares and stores tissue from Radboudumc patients on a large scale. This is carried out in a uniform and well documented manner.
1. Opt-out
Left-over tissue in the Pathology Department’s diagnostic archive – from patients who have not signed an informed consent and:Have not objected to further use of their tissue for research and education purposes via mijnRadboud.
OR
Have objected to further use of their tissue for research and education purposes (this tissue remains available for diagnostic purposes only).
Both resection material and biopsies in this category are stored in the Pathology department’s diagnostic archive.
2. Opt-in
Left-over tissue for the Radboud Biobank – from patients who have signed an informed consent for one of the sub-biobanks accommodated by the Radboud Biobank.Resection tissue comes from the clinical setting via the central reception of the tissue preparation area and is eventually stored at the Radboud Biobank. In general 4 tissue blocks are stored (2x unaffected tissue, fresh frozen and paraffin embedded) plus 2x affected tissue samples, fresh frozen and paraffin embedded). The blocks are approximately 0,5 cm3. If desired it is possible to store more blocks depending on the size of the resected tissue. The maximum number of blocks is 16 (4x fresh frozen unaffected, 4x paraffin embedded unaffected, 4x fresh frozen affected, 4x paraffin embedded affected).
Biopsies are handled by the Pathology department according to the secondary use protocol, i.e. the tissue is prepared in the routine manner. Should (a part of) a biopsy be desired for research purposes and before the research proposal is presented to the CMO-light, the Radboud Biobank will check if there is enough tissue for the issuance and if both the sub-biobank and the pathologist concerned agree to the issuance.
N.B. Taking extra biopsies for a sub-biobank initiative is not permitted. A concrete research proposal with a specific informed consent that must be reviewed by the Radboudumc CMO commission is required for an extra biopsy (i.e. this research falls under the Dutch WMO legislation).
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
One year since the new business model for the Radboud Biobank was implemented
3 March 2026The new business model was introduced last year, with departments paying half of the biomaterial processing costs, covering the storage costs, and applying a graduated rate for sample issuance.
go to page
Periodic invoicing biobank collections
3 March 2026Since 2025, the Radboud Biobank periodically charges all biobank collections for the processing and storage costs incurred.
go to page
The purpose of a central biobank facility such as the Radboud Biobank
3 March 2026As the central biobank facility of Radboudumc, the Radboud Biobank does more than simply store human biomaterials.
go to page
Radboud Biobank's 2025 annual report
3 March 2026The Radboud Biobank's 2025 annual report is now available on request.
go to page
Aevai Health developed a virtual assistant
3 March 2026Aevai Health has developed Alva - a virtual assistant to engage research participants, which can support participants with health literacy, understanding research protocols, and with using measurement devices.
go to page
Radboudumc Researchers Highlight Critical Gaps in Reporting Pre-Analytical Processes in Biobanked Biomaterials
21 October 2025Radboudumc Researchers have identified significant shortcomings in pre-analytical sample processing reporting in clinical biomarker research, a factor crucial for study reliability and replicability.
go to page